TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged \>17 years (male and female)~* HCV infection PCR positive~* ALT \> 40 iu/ml~* Ishak fibrosis score (within last 5 years) \> 2, \< 5~* Informed consent~* Failed antiviral therapy for HCV in last 5 years~Exclusion Criteria:~* Patients requiring anticoagulation for existing clinical indications~* Active peptic ulcer disease~* Past history of haemorrhagic stroke~* Thrombocytopaenia (platelets count \< 100 x 109 /L)~* Clinical evidence of portal hypertension~* Known cerebrovascular abnormalities;~* HIV antibody positive;~* Alcohol abuse (\>40 unites/week)~* Menhorragia~* Pregnancy

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Warfarin anticoagulation (Type: EXPERIMENTAL): Anticoagulated with warfarin to maintain an INR of 2-3 between 8 and 16 weeks (treatment period).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent~* Male or female subjects 12-45 years of age~* Documented history of perennial allergic rhinitis~* General good health~* Other criteria apply~Exclusion Criteria:~* History of physical findings of nasal pathology (within 60 days prior to Screening Visit 1)~* Participation in any investigational drug study 30 days preceding Screening Visit 1~* History of respiratory infection/disorder with 14 days preceding Screening Visit 1~* Use of any prohibited concomitant medications

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.
- BDP HFA 320 µg/day (Type: EXPERIMENTAL): Participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning for 6 weeks (42 days). During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.
- Prednisone (Type: ACTIVE_COMPARATOR): Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a 10/mg a day prednisone capsule.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who meet the UK Parkinson's Disease Society Brain Bank Research Center clinical diagnostic criteria for PD.~* Hoehn and Yahr stages 1-2.5 at initial recruitment in baseline study.~* Absence of dementia confirmed by neuropsychological testing at initial recruitment in baseline study.~Exclusion Criteria:~* contra-indication for magnetic resonance study~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group 1 Parkinson disease subjects (Type: None): Subjects with Parkinson disease who previously participate in a motor and brain PET (brain positron emission tomography) imaging study who were invited for a longitudinal observational study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Treatment for Gynaecological Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients aged 18 to 75 years.~* Scheduled to undergo a total or subtotal abdominal hysterectomy (with or without salpingo-oophorectomy) for benign conditions.~* Patients experiencing pain at rest of at least moderate intensity the day after surgery.~Exclusion Criteria:~* Patients not suitable for study treatments and rescue medication (RM) or those for whom non-steroidal anti-inflammatory drugs (NSAIDs), opioids, acetyl salicylic acid, pyrazolones or pyrazolidines are contraindicated.~* Patients with clinically significant abnormalities in vital signs, safety laboratory tests and 12-lead ECG at screening.~* Patients with history of any illness or condition that might pose a risk to the patient or confound the efficacy and safety study results.~* Patients using and not suitable to withdraw analgesics other than those specified in the protocol.~* Patients using and not suitable for withdrawing any of the prohibited medication specified in the protocol.~* Breastfeeding women.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- DKP/TRAM followed by DKP/TRAM (Type: EXPERIMENTAL): Dexketoprofen/Tramadol-single dose followed by Dexketoprofen/Tramadol-multiple doses
- DKP followed by DKP (Type: ACTIVE_COMPARATOR): Dexketoprofen-single dose followed by Dexketoprofen-multiple doses
- TRAM followed by TRAM (Type: ACTIVE_COMPARATOR): Tramadol-single dose followed by Tramadol-multiple doses
- Placebo followed by DKP/TRAM (Type: OTHER): Placebo single dose followed by Dexketoprofen/Tramadol-multiple doses
- Placebo followed by DKP (Type: OTHER): Placebo single dose followed by Dexketoprofen-multiple doses
- Placebo followed by TRAM (Type: OTHER): Placebo single dose followed by Tramadol-multiple doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Treatment of Glabellar Frown Lines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient females 18 to 50 years of age~* Moderate to severe glabellar frown lines~Exclusion Criteria:~* Glabellar Frown Lines at rest rating 3 on the 4-point Facial Wrinkle Scale~* Previous treatment with botulinum toxin~* Previous treatment with biodegradable fillers in glabellar area within last 12 months~* Any severe or uncontrolled systemic disease, malignant tumor, or medical history of HIV infection~* Known hypersensitivity to incobotulinumtoxinA or onabotulinumtoxinA or to any of their excipients~* Intake of any of the forbidden concomitant medication or other agents that might interfere with neuromuscular function or might interfere with the action of botulinum toxin type within 14 days prior to injection

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- IncobotulinumtoxinA (Type: EXPERIMENTAL): 20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points
- OnabotulinumtoxinA (Type: ACTIVE_COMPARATOR): 20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Three-times-weekly Versus Daily Growth Hormone (GH) Treatment in naïve GH-deficient Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Growth hormone deficiency clinically and biochemically demonstrated~Exclusion Criteria:~* Children affected by multiple pituitary hormone deficiency or receiving any other kind of hormonal replacement therapy or drug and GHD children with a shorter follow-up

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- group A (Type: ACTIVE_COMPARATOR): Sixteen growth hormone (GH) deficiency children were assigned to receive daily growth hormone therapy for 12 months. The investigators used an initial weekly dose of 0.175 mg/kg (corresponding to the daily dose of 0.025 mg/Kg) of GH with a gradual increase every 6 months in order to always maintain the insulin growth factor (IGF)-I levels in the normal range. In detail, from months 1 to 6 the investigators used the mean weekly dose of 0.175 mg/kg and from months 6 to 12 the mean weekly dose of 0.20 mg/kg.
- group B (Type: ACTIVE_COMPARATOR): Sixteen growth hormone (GH) deficiency children were assigned to receive three time weekly growth hormone therapy for 12 months. The investigators used an initial weekly dose of 0.175 mg/kg (corresponding to the daily dose of 0.025 mg/Kg) of GH with a gradual increase every 6 months in order to always maintain the insulin growth factor (IGF)-I levels in the normal range. In detail, from months 1 to 6 the investigators used the mean weekly dose of 0.175 mg/kg and from months 6 to 12 the mean weekly dose of 0.20 mg/kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven previously untreated invasive carcinoma of the uterine cervix~  * Squamous cell carcinoma~ * Adenosquamous carcinoma~ * Adenocarcinoma~* TNM classification stage IIIB or IVA (FIGO classification stage IB, IIA, IIB, IIIA, IIIB, or IVA)~* Cytologically or histologically proven metastases to the para-aortic lymph nodes~* No more than 8 weeks since diagnosis~* No metastases to scalene nodes, intraperitoneal metastases, or metastases to other organs outside the radiation field at the time of original clinical and surgical staging~  * Negative CT scan of the chest~* Patients with ureteral obstruction must be treated with stent or nephrostomy tube~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* GOG 0-2~Life expectancy:~* At least 6 months~Hematopoietic:~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 1.5 times normal~* SGOT no greater than 3 times normal~Renal:~* Creatinine less than 2.0 mg/dL~* No renal abnormalities (e.g., pelvic kidney, horseshoe kidney, or renal transplantation) requiring modification of radiation fields~Other:~* Not pregnant~* No septicemia or severe infection~* No other invasive malignancy within the past 3 years except nonmelanoma skin cancer~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior cytotoxic chemotherapy for this or other malignancy~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy for this or other malignancy~* No prior radiotherapy to pelvis or abdomen~Surgery:~* Not specified~Other:~* No other prior therapy for this malignancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiation therapy plus concurrent weekly chemotherapy (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria Inclusion criteria~1. Patients scheduled to undergo a primary, unilateral elective total knee replacement~2. Male or Female 20 years of age or order~3. Patients weighing at least 40 kg~4. Written informed consent prior to the start of study participation~Exclusion criteria Exclusion criteria~1. History of bleeding diathesis~2. Constitutional or acquired coagulation disorders that in the investigator's judgment puts the patient at excessive risk for bleeding~3. Major surgery or trauma (e.g. hip fracture) within the last 3 months~4. Recent unstable cardiovascular disease, such as uncontrolled hypertension at the time of enrollment (investigator's judgment) or history of myocardial infarction within the last 3 months~5. Any history of hemorrhagic stroke or any of the following intracranial pathologies: bleeding, neoplasm, AV (arteriovenous) malformation or aneurysm or recent bleeding history~6. Condition requiring anti-coagulant therapy~7. Elevated AST(Aspartate Aminotransferase) , ALT(Alanine Aminotransferase), or any history of clinically relevant liver disease~8. Patients with a history of clinically significant renal diseases or with elevated creatinine values

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dabigatran etexilate 110 mg (Type: EXPERIMENTAL): Dabigatran etexilate 110 mg capsule, once a day, oral administration
- Dabigatran etexilate 150 mg (Type: EXPERIMENTAL): Dabigatran etexilate 150 mg capsule, once a day, oral administration
- Dabigatran etexilate 220 mg (Type: EXPERIMENTAL): Dabigatran etexilate 110 mg capsule, 2capsules, once a day, oral administration
- Placebo (Type: PLACEBO_COMPARATOR): matching placebo capsule, once a day, oral administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Left ventricular ejection fraction \<45%, as assessed by echocardiography, a multigated acquisition (MUGA) scan or magnetic resonance imaging (MRI) scan within 18 months~* On stable chronic guideline-directed therapy for HF including chronic loop diuretics, ACEi, ARBs, MRAs, ARNI or / and β-blockers as tolerated, with no changes of these medications in the past 2 weeks~* At least an oral dose of 40 mg of furosemide/day or equivalent (20 mg torsemide, 1 mg bumetamide)~Exclusion Criteria:~* SBP \< 115 mm Hg or \> 180 mm Hg at screening or pre-randomization~* Heart rate \< 50 beats per minute (bpm) or \> 120 bpm at screening or pre-randomization~* Primary HF etiology attributable to either restrictive/obstructive cardiomyopathy, idiopathic hypertrophic or uncorrected severe valvular disease~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo+Diuretic to BMS-986231+Diuretic (Type: EXPERIMENTAL): Administered in a cross over design with 8-hour continuous infusions and 7-28 day wash-out periods
- BMS-986231+Diuretic to Placebo+Diuretic (Type: EXPERIMENTAL): Administered in a cross over design with 8-hour continuous infusions and 7-28 day wash-out periods

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine Treatment of Major Depression and Chronic Low Back Pain For Older Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>/= 60~* Current episode of MDD per SCID DSM-IV criteria~* Must score \>/= 16 on the CES-D assessment~* Serum sodium \>/=130 mEq/ml~* CLBP of at least moderate severity for more days than not for \>/= 3 months~* MADRS score \>/= 15~* Sufficiently medically stable to be able to participate in a depression treatment protocol~* Willingness and ability to speak English Access to translators is limited. It would be unsafe to treat an older adult who does not speak English with an antidepressant and not be able to effectively communicate with them about their progress and any side effects. We provide a 24/7 on-call service for all subjects enrolled in this study. The on-call clinicians and physicians are not bilingual, and if a problem arose, it may be impossible to effectively interpret and manage the emergent situation. Finally, many of the assessments used in the study are self-reports. At the present time, we do not have the ability to translate these instruments into other languages. If the subject cannot read and understand English, this would interfere with their ability to complete the self-report assessments~* Willingness to discontinue other antidepressants and anxiolytics, except for lorazepam up to 2 mg/day~* Mini Mental State Exam \> 20~* Willingness to provide informed consent~* Corrected visual ability that enables reading of newspaper headlines and hearing capacity that is adequate to respond to a raised conversational voice.~Exclusion Criteria:~* Meet DSM-IV criteria for dementia~* History of bipolar, schizophrenia, schizoaffective, or other psychotic disorder~* Alcohol or other drug abuse (including abuse of prescription medications) within the past 6 months~* History of treatment non-adherence in other protocols run by the Mid-Life or Late-Life Centers~* Acute pain superimposed on chronic pain. For example, subjects who report red flags which suggest a herniated disk, vertebral fracture, infection, cauda equina syndrome, or other medical emergency will be excluded~* Wheelchair bound~* History of documented non-response to duloxetine~* Concurrent use of thioridazine~* Active suicidal ideation with plan~* Uncontrolled narrow angle glaucoma

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Duloxetine + clinical management~NOTE -- THIS WORK WAS CONDUCTED AS PART OF A CAREER DEVELOPMENT AWARD. THE CLINICALTRIALS.GOV DESCRIPTION OF THE STUDY WAS UPDATED 1/5/16 TO UPDATE THE OPEN LABEL NATURE OF THIS WORK. THIS IS WHAT IS REPORTED HERE AND HAS BEEN PEER REVIEWED AND PUBLISHED.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients, ages 18 years or older who have signed the informed consent~* Has qualifying bacterial pneumonia~* Female patients must not be pregnant at the time of enrollment~* Must agree to a reliable method of birth control during the study and for 30 days following the last dose of study drug~Exclusion Criteria:~* Known or suspected hospital-acquired pneumonia~* Evidence of significant immunological disease~* Has a history of hypersensitivity or allergic reaction to any tetracycline or to any fluoroquinolone antibiotic~* Has received an investigational drug within past 30 days~* Women who are pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Omadacycline (Type: EXPERIMENTAL): Omadacycline IV; Omadacycline tablets
- Moxifloxacin (Type: ACTIVE_COMPARATOR): Moxifloxacin IV; Moxifloxacin tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mantel Cell Lymphoma Efficacy of Rituximab Maintenance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* mantle cell lymphoma~* Initial immunophenotyping with CD20 and CD5.~* CD20+.~* t (11;14) by karyote, FISH, molecular biology or immunohistochemistry (Bcl-1)~* Patient no previous treated.~* At least one tumor site accessible for assessment~* Aged \> 18 years \< 65~* ECOG \< or = 2.~* No other neoplasms apart from resected basal cell carcinoma or in situ carcinoma.~* signed informed consent~* FEVG 50%~Exclusion Criteria:~* other type of lymphoma~* ECOG \> or = 3~* relapse~* serology VIH + Hepatite +~* diabetis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): observation : 3 years maintenance period with assesments and surveillance every 2 months
- 2 (Type: EXPERIMENTAL): maintenance period infusions of Rituximab 375 mg/m2/2 months and assessement and surveillance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete